You are here

Positive Phase II Results for Miravirsen in HCV Infection

First RNA-targeted drug to enter clinical trials (Mar. 27)

Positive results from a new phase IIa study of miravirsen (Santaris Pharma), a pan-hepatitis C virus (HCV) genotype-1 antiviral agent, have been published online in the New England Journal of Medicine. Miravirsen is the first microRNA-targeted drug to enter clinical trials for the treatment of HCV infection.

In the new study, 4 weeks of miravirsen monotherapy provided dose-dependent antiviral activity, with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL).

Other findings included:

  • Miravirsen was safe and well tolerated, and provided prolonged antiviral activity well after the last dose of miravirsen monotherapy (five weekly injections).
  • There were no signs of viral resistance.
  • Adverse events were infrequent and mild, and did not lead to discontinuation of the study drug.
  • There were no dose-limiting toxicities or discontinuations due to adverse events.
  • Miravirsen was associated with dose-dependent reductions in HCV RNA that were sustained well beyond the end of the four-week dosing period.
  • Four out of nine patients treated at the highest dose (7 mg/kg) had undetectable HCV RNA after five weekly doses of miravirsen monotherapy.

The randomized, double-blind, placebo-controlled phase IIa study assessed the safety and tolerability of miravirsen in treatment-naïve patients with chronic HCV genotype-1 infection. The patients were randomly assigned to three cohorts (nine active-treatment and three placebo patients per cohort) at miravirsen doses of 3, 5, and 7 mg/kg. Miravirsen was administered as a total of five weekly subcutaneous injections over 29 days.

Miravirsen inhibits miR-122, a liver-specific microRNA that HCV requires for replication. Miravirsen is designed to recognize and sequester miR-122, making it unavailable to HCV. As a result, viral replication is inhibited, and the level of HCV infection is reduced.

Sources: Santaris Pharma; March 27, 2013; and NEJM; March 27, 2013.

More Headlines

Non-Invasive Therapy for Patients Who are Nonresponsive to Antidepressants
Vials Being Rationed, Only One Manufacturer
Several Health Insurers Now Consider DBS Therapy for Epilepsy a Covered Indication
Disease Occurs in 1 in 5,000 Male Births in the U.S.
Drug Has Potential Role In Oxidative Stress, Inflammation, and Neurodegeneration
OCA Meets Primary Endpoint of Improvement in Liver Fibrosis
Scan Could Improve Understanding of Dopamine Function in Schizophrenia
Liver Fluke Infestation Affects Almost 2.5 Million People Globally